Cannabinoids as potential new analgesics

Life Sciences

Volumn 65, Issue 6-7, 1999, Pages 675-685

  Fuentes, José A ^a   Ruiz Gayo, Mariano ^a   Manzanares, Jorge ^a,b   Vela, Gema ^a   Reche, Ignacio ^a   Corchero, Javier ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b INSTITUTO PLURIDISCIPLINAR   (Spain)

Author keywords

Cannabinoids; Enkephalin degrading enzyme inhibitors; Morphine; Nociception; Opioids

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; AMINOPEPTIDASE; ANALGESIC AGENT; ANANDAMIDE; BESTATIN; BETA ENDORPHIN; CANNABINOID; CANNABINOID RECEPTOR; DRONABINOL; DYNORPHIN; ENDORPHIN; ENKEPHALIN[2 DEXTRO ALANINE 4 METHYLPHENYLALANINE 5 GLYCINE]; ENZYME INHIBITOR; MESSENGER RNA; METENKEPHALIN; MORPHINE; NABILONE; OPIATE RECEPTOR; RIMONABANT; SYNTHETASE;

ANTINOCICEPTION; ARTICLE; DOSE RESPONSE; HUMAN; NEUROMODULATION; NOCICEPTION; NONHUMAN; PAIN;

ANALGESIA; ANALGESICS; ANIMALS; CANNABINOIDS; HUMANS; NOCICEPTORS; OPIOID PEPTIDES; RECEPTORS, CANNABINOID; RECEPTORS, DRUG;

ANIMALIA;

EID: 0033538562     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0024-3205(99)00290-8     Document Type: Article

References (41)

1. R. G. Pertwee, Pharmaceutical Sci. 3 539-545 (1997).
2. U. Herzberg, E. Eliav, G.J. Bennett, and I.J. Kopin, Neuroci Lett 221 157-160 (1997).
3. G. Jr. Pugh, D.J. Jr. Mason, V. Combs and S.P. Welch, J. Pharmacol. Exp. Ther. 281 730-737 (1997).
4. D.R. Compton, M.D. Aceto, J. Lowe, and B.R. Martin, J.Pharmacol.Exp.Ther. 277 586-594 (1996).
5. P.B. Smith, D.R. Compton, S.P. Welch, R.K. Razdan, R. Mechoulam and B.R. Martin. J. Pharmacol. Exp. Ther. 270 219-227 (1994).
6. L. Smith, K. Fujimori, J. Lowe and S. Welch Pharmacol Biochem Behav 60 183-191 (1998).
7. J.A. Vivian, S. Kishioka, E.R. Butelman, J. Broadbeard, K.O. Lee and J.H. Woods, J. Pharmacol. Exp. Ther. 286 697-703 (1998).
8. A.K. Jain, J.R. Ryan, F.G. McMahon and G. Smith, J. Clin. Pharmacol. 21 320S-326S
9. R. Noyes, S.F. Brunk, D.H.Avery and A. Canter Clin. Pharmacol. Ther. 18 84-89 (1975).
10. R. Noyes, S.F. Brunk, D.A. Baram and A. Canter Clin. Pharmacol. Ther. 15 139-143 (1975).
11. W. Notcutt, M. Price and Chapman, G. Pharmac. Sci. 3 551-555 (1997).
12. L. A. Matsuda, S. J. Lolait, M.J. Brownstein, A.C. Young and T. I. Bonner. Nature 346 561-564 (1990).
13. S. Munro, K. L. Thomas and M. Abu-Shaar Nature 365 61-65 (1993).
14. W. A. Devane, L. Hanus, A. Breuer, R. G. Pertwee, L. A. Stevenson, G. Griffin, D. Gibson, A. Mandelbaum, A. Etinger and R. Mechoulam Science 258 1946-1949 (1992).
15. M. Herkenham, A. B. Lynn, M. R. Johnson, L. S. Melvin, B. R. De Costa and K. C. Rice J. Neurosci. 11 563-583 (1991).
16. W.J. Martin, S.L. Patrick, P.O. Coffin, K. Tsou and J.M. Walker, Life Sci. 56 2103-2110 (1995).
17. M. Rinaldi-Carmona, F. Barth, M. Michel-Heaulme, D. Shire, B. Calandra, C. Congy, S. Martinez, J. Maruani, G. Neliat, D. Caput, O. Ferrara, P. Soubrie, J.C. Brelire and G. Le Fur FEBS Letters 350 240-244 (1994).
18. J.D. Richardson, L. Aanonsen, K.M. Hargreaves Eur. J. Pharmacol. 319 R3-R4 (1997).
19. S. Kaymatkalan, I.H. Ayhan, F.C. Tulinay, Psychopharmacology 55 243-249 (1977).
20. G. Vela, J.A Fuentes, A. Bonnin, J.J. Fernandez Ruiz, M. Ruiz Gayo, Brain Research 680 142-147 (1995a).
21. H.P. Rang and M.M. Dale, Pharmacology 2nd Edition (Churchill Livingstone, eds.), pp. 458-459, Edinburgh (1991).
22. B. Hine, E. Friedman, M. Torrelio, S. Gerbson, Science, 187 443-445 (1975).
23. G. Vela, M. Ruiz-Gayo, J.A. Fuentes, Neuropharmacology 34 665-668 (1995b).
24. M.S. Kumar, M. Haney, T. Becker, M.L. Thompson, R.M. Kream and K. Miczek, Brain Res. 525 78-83 (1990).
25. A.H. Lichtman, and B.R. Martin, J. Pharmacol. Exp. Ther. 258 517-523 (1991).
26. P.J.J. Vaysse, E.L. Gardner, and R.S. Zukin, J. Pharmacol. Exp. Ther. 241 534-539 (1987).
27. J. Corchero, M.A. Avila, J.A. Fuentes and J. Manzanares, Life Sci. 61 39-43 (1997).
28. J.Manzanares, J. Corchero, J. Romero, J.J. Fernandez Ruiz, J.A. Ramos and J.A. Fuentes. Mol Brain Res 55 126-132 (1998).
29. S.P. Welch. J. Pharmacol. Exp. Ther. 265 633-640 (1993).
30. I.D. Meng, B.H. Manning, W.J. Martin and H.L. Fields Nature 395 381-383 (1998).
31. I. Reche, J.A. Fuentes, M. Ruiz-Gayo Eur. J. Pharmacol. 301 75-81 (1996a).
32. S.P. Welch, and D.L. Stevens. J. Pharmacol. Exp. Ther. 262 10-17 (1992).
33. I. Reche, J.A. Fuentes, M. Ruiz-Gayo Eur. J. Pharmacol 318 11-16.(1996b).
34. S.N. Thorat, and H.N. Bhargava Eur. J. Pharmacol. 260 5-13 (1994).
35. S.P. Welch Drug Alcoh. Depend. 45 39-45.(1997).
36. D.W. Rowen, J.P. Embrey, C.H. Moore and S.P. Welch Pharmacol. Biochem. Behav. 59 399-404 (1998).
37. A.H. Lichtman and B.R. Martin, Pharmacol. Biochem. Behav. 57 7-12 (1997).
38. A. Calignano, G. La Rana, A. Giuffrida and D. Piomelli Nature 394 277-281 (1998).
39. B.P. Roques, M.C. Fournie-Zaluski, E. Soroca, Nature 288 286-288 (1980).
40. A. Safavi and L.B.Hersh, J Neurochem 65 389-95 (1995).
41. W. Hall and N. Solowij, Lancet 352 1611-16 (1998).